



The Nifty ended 1.19% up at 17132.20. It opened on a positive note and touched days high 17153.50 towards finishing off with a bullish body candle. As of now, the benchmark index looks overstretched. However, considering the broader uptrend, we prefer buy on dips as long as critical supports are intact. Immediate support is placed 17000. Critical resistance is placed around 17220 levels.

On the Nifty hourly chart, leading indicators have reached overbought zone suggesting intraday retracement towards 17000 levels. However, sharply rising ADX is pointing towards range bound oscillation with a positive bias in the price band of 17000-17220.

Nifty patterns on multiple periods suggest; it is moving higher and higher despite the Bank Nifty remained range bound is a concern. Hence, staying cautious on rise is advised. Pullback in oversold sector leaders helped the Benchmark Index moving higher. Critical resistance is placed around 17220 levels.

Nifty Crucial Supports & Resistances-

Supports- 17000, 16950 Resistances- 17150, 17220

Open Positional Calls-

T+7 Positional Sell-
|Futures Segment| JSW STEEL Sep
Fut @ 700-705, TGT- 665, Closing SL
- above 725

T+7 Positional Sell-
|Futures Segment| TATA MOTORS
Fut @ 290-292, TGT- 272, Closing SL
- above 302

T+3 Positional Buy
|Cash Segment| CESC @ 804-800,
TGT- 840, SL- closing below 780

BTST Positional Buy
|Cash Segment| TVS MOTOR @ 523
-522, TGT- 542, SL- closing below
512

BTST Positional Buy
|Cash Segment| PIDILITE @ 2282-
2280, TGT- 2320, SL- closing below
2260

Key Contents	Page No.
Domestic News	4

Nifty Intraday Chart



Market in Retrospect

India's stock benchmarks closed at record aided by gains in telecom, technology, metals and banking stocks. Investors will look forward to India's GDP data scheduled to be released later today, to assess the pace of economic recovery.

Nifty index ended 1.19% higher at 17,132. The broader markets represented by the NIFTY 500 Index ended 1.10% higher, ending at 14,556. Among the sectorial indices, NIFTY Consumption was the top gainer, gaining by 1.91%, followed by NIFTY Metal gaining by 1.54%. NIFTY Media was the top loser, losing by 0.12%.

Bharti Airtel was the top gainer, gaining by 7.03%, followed by Bajaj Finance and Eicher Motors gained by 5.01% & 4.91% respectively. Tata Motors was the top loser, losing by 1.59%, followed by Nestle India and Indusind Bank which fell by 1.39% & 1.26% respectively.

The Advance : Decline ratio stood at 969:965

Market Turnover (In Crore) 31-08-2021

Name	Last	Previous
NSE Cash	*NA	60454.78
NSE F&O	5563110.62	4397477.59
BSE Cash	6,221.24	4,459.72
BSE F&O	*NA	42.85

FII Derivatives Flow (In Crore) 30-08-2021

Instrument	Purchase	Sale	Net
Index Future	4134.88	3576.97	557.91
Index Option	301168.37	299955.45	1212.92
Stock Future	13455.35	12009.35	1446
Stock Option	13585.43	13397.52	187.91

Institutional Flow (In Crore) 30-08-2021*

Institution	Purchase	Sale	Net
FII	8408.62	7205.81	1202.81
DII	6678.62	5989.77	688.85

*Data not updated till 5:50PM

NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Bharti Airtel	7.03	7.09	59661820	19097480
Bajaj Finance	5.01	7.80	2946438	1561507
Eicher Motors	4.91	5.16	2381821	781453
Hindalco Industries	4.52	11.27	20847646	13602950
Shree Cement	4.16	7.83	102061	37878

NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
BPCL	0.19	3.34	9001236	5336686
RIL	0.53	3.41	12223037	6307997
Indusind Bank	1.26	1.26	3138652	2364846
Nestle India	1.39	1.58	227370	83102
Tata Motors	1.59	2.68	36951003	23537160

Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>

Sensex Intraday Chart



Market in Detailed (Updated after 4:00 PM)

Indian Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	57552.39	662.63	1.16	2.85	9.44	10.81	48.99
Nifty	17132.20	201.15	1.19	3.05	8.69	9.94	50.45
BSE M Cap	23853.43	197.05	0.83	4.55	3.32	9.63	62.70
BSE S Cap	26919.94	229.66	0.86	4.39	0.50	14.09	87.78
Nifty MC 100	28417.25	174.85	0.62	4.18	2.16	10.25	70.34
BSE Auto	22571.39	142.00	0.63	2.08	0.37	4.12	27.63
BSE Capgoods	24973.86	138.13	0.56	4.82	5.50	11.00	81.74
BSE FMCG	14580.82	124.88	0.86	3.09	8.16	11.04	28.48
BSE Metal	20579.75	249.17	1.23	4.26	2.06	9.02	132.97
BSE Oil&Gas	17083.96	198.76	1.18	5.78	10.63	3.71	30.58
BSE Healthcare	26569.77	341.35	1.30	3.14	1.58	8.29	44.50
BSE Power	2921.29	34.24	1.19	7.33	11.65	3.72	74.94
BSE Realty	3084.98	9.22	0.30	2.62	3.06	15.11	75.44
BSE ConsDur	37360.66	567.96	1.54	3.31	2.68	11.89	64.16
BSE Bank	41469.62	156.52	0.38	2.43	5.82	2.79	53.75
BSE IT	34180.47	398.31	1.18	1.47	10.81	23.91	89.31

Bond Markets							
Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	1.29	0.02	1.18	0.01	5.83	18.86	83.54
UK	0.67	0.09	16.09	24.72	18.76	15.60	115.76
Brazil	3.82	0.05	1.19	2.55	1.41	1.87	4.92
Japan	0.03	0.00	13.64	38.89	13.64	71.26	50.98
Australia	1.16	0.01	0.43	0.35	2.20	32.50	17.62
India	6.22	0.01	0.15	0.54	0.19	3.22	1.62
Switzerland	0.33	0.01	3.49	13.09	10.99	107.50	19.02
Germany	0.40	0.04	9.11	16.53	13.45	113.37	0.50

Currency							
Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	73.01	0.26	0.36	1.62	1.83	0.54	0.84
USD Index	92.52	0.14	0.15	0.41	0.37	2.76	0.40
YUAN	6.46	0.00	0.06	0.14	0.01	1.43	5.97
GBP	1.38	0.00	0.07	0.30	0.81	3.11	2.99
EUR	1.18	0.00	0.32	0.67	0.29	3.21	0.85
YEN	109.93	0.01	0.01	0.25	0.56	0.32	3.66

Freight							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	4235.00	40.00	0.95	3.49	28.65	63.14	184.61
Baltic Dirty	604.00	0.00	0.00	0.49	0.00	0.00	27.43
SG Dubai HY	1.53	0.17	12.50	118.57	292.31	91.25	447.73

Global Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	35399.84	55.96	0.16	0.18	1.33	2.52	24.52
Nasdaq	15265.89	136.39	0.90	2.16	4.04	11.03	29.64
S&P 500	4528.79	19.42	0.43	1.10	3.04	7.72	29.38
FTSE100	7109.13	38.06	0.53	0.01	1.10	1.24	19.22
CAC40	6670.32	16.60	0.25	0.10	0.88	3.47	34.84
DAX	15877.31	7.94	0.05	0.17	2.15	2.97	22.66
Mexico IPC	52602.07	176.43	0.34	1.05	3.41	3.37	42.78
Brazil Bovespa	119740.0	937.60	0.78	1.93	1.69	5.13	20.50
Russian RTS	1684.73	0.13	0.01	1.43	3.62	5.45	33.84
Japan Nikkei	28089.54	300.25	1.08	1.29	2.95	2.67	21.39
Hang Seng	25878.99	339.45	1.33	0.59	0.32	11.23	2.79
Taiwan Index	17490.29	93.77	0.54	3.99	1.41	2.47	38.91
Shanghai Comp	3543.94	15.79	0.45	0.84	4.31	1.98	4.37
KOSPI	3199.27	55.08	1.75	1.94	0.10	0.15	37.53
Malaysia KLCI	1601.38	11.22	0.71	5.19	7.14	1.13	4.99
Jakarta Comp	6150.30	5.40	0.09	1.00	1.32	3.41	17.41
Philippine SE	6855.44	68.82	1.01	4.00	9.33	2.71	16.51
Thai Exch	1638.75	4.98	0.30	3.26	7.68	2.83	25.03

Indian Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	68.60	0.62	0.90	1.55	7.25	3.42	60.97
BRENT Crude	72.87	0.64	0.87	2.42	3.50	6.31	51.19
Natural Gas	4.29	0.02	0.39	9.50	9.39	42.13	50.99

LME							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1813.08	2.87	0.16	0.57	0.05	4.91	7.86
Silver(\$/Ounce)	24.06	0.03	0.12	0.85	5.60	14.14	14.49
Aluminium	2675.25	37.50	1.42	4.39	7.16	9.14	53.44
Copper	9423.75	108.75	1.17	4.20	3.25	7.66	41.91
Zinc	2990.70	1.55	0.05	2.30	0.72	1.75	21.57
Lead	2444.75	1.25	0.05	0.11	3.36	10.68	24.91

Agro Commodities							
Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	200.60	0.70	0.35	7.99	9.95	20.12	50.83
Cotton	93.34	0.89	0.94	0.89	4.42	12.03	42.63
Sugar	20.08	0.14	0.69	2.55	12.12	15.47	57.99
Wheat	718.25	5.25	0.73	1.91	0.74	6.45	24.21
Soybean	1304.50	1.25	0.10	2.05	3.32	4.97	38.59

Abbott introduces single-dose formulation of carbetocin in India

Abbott has launched room-temperature-stable, single-dose formulation of carbetocin in India to help in the prevention of postpartum haemorrhage (PPH). PPH refers to excessive blood loss of 500 ml or more after vaginal delivery and 1,000 ml or more after a caesarean procedure, within 24 hours of childbirth. Although preventable, PPH is associated with almost 20 per cent maternal mortality in the country. PPH, if left untreated, can result in complications like anaemia in the postpartum period or aggravate mental health problems including postnatal depression and post-traumatic stress disorder apart from other issues. The current prevention and treatment protocol for PPH requires cold-chain storage and distribution, as well as continual administration of medicines via intravenous drip infusion. This can impede access to quality healthcare for pregnant women in care settings where these requirements may not be feasible.

Hero Electric partners with Wheels EMI to offer easy financing options to customers

Hero Electric has partnered with two-wheeler life cycle management company Wheels EMI for offering easy financing options to customers buying electric two-wheelers. Besides vehicle financing, the partnership also offers extra benefits to Hero Electric customers such as attractive interest rates, flexible tenure options and affordable equal monthly instalments (EMIs) as per customer eligibility. As a preferred financial partner, Wheels EMI will provide Hero Electric customers with simple and fast disbursals with minimum documentation.

Sun Pharma gets exclusive right to commercialise Winlevi acne cream in US, Canada

Sun Pharma and specialty pharma firm Cassiopea SpA announced consummation of their exclusive licence and supply agreements for Winlevi cream used for treatment of acne vulgaris in patients 12 years and older. The agreements are effective from August 31, 2021. Sun Pharma now has the exclusive right to commercialise Winlevi in the US and Canada. Cassiopea will be the exclusive supplier of the product, which is expected to be available in the US in the fourth quarter of 2021. The US Food and Drug Administration (USFDA) approved Winlevi (clascoterone cream 1 per cent) in August 2020 for the topical treatment of acne vulgaris in patients 12 years and older.

Dr Reddy's launches generic stomach ulcer drug in US market

Dr Reddy's Laboratories has launched generic Chlordiazepoxide Hydrochloride and Clidinium Bromide capsules used for treatment of stomach ulcers, irritable bowel syndrome and inflammation of the colon, in the US market. The company has launched Chlordiazepoxide Hydrochloride and Clidinium Bromide capsules USP, 5 mg/2.5 mg in the US market. The product is a generic version of Librax capsules. According to IQVIA Health data, Librax brand and generic had US sales of approximately USD 105.9 million moving annual total (MAT) for the most recent twelve months ending in July 2021. The company's capsules, USP, are available in one strength of 5 mg/2.5 mg capsules in bottle count sizes of 100.

NTPC Darlipali Thermal Power Station's Unit 2 to start commercial operation from September 1

NTPC the second unit of Darlipali Super Thermal Power Station in Odisha will start commercial operation from September 1. The Unit-1 of Darlipali power project had started commercial operation in March 2020. With this, the commercial capacity of NTPC and NTPC group will become 53,225 MW and 66,650 MW respectively.

CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.

Company	Details
Bannari Amman Sugars Ltd	Cash dividend of INR10 effective 01-09-2021
LG Balakrishnan & Bros Ltd	Cash dividend of INR10 effective 01-09-2021
JB Chemicals & Pharmaceuticals Ltd	Cash dividend of INR8 effective 01-09-2021
TPL Plastech Ltd	Cash dividend of INR3.50 effective 01-09-2021
Josts Engineering Co Ltd	Cash dividend of INR3 effective 01-09-2021
GeeCee Ventures Ltd	Cash dividend of INR1.90 effective 01-09-2021
Lambodhara Textiles Ltd	Cash dividend of INR1 effective 01-09-2021
KPR Mill Ltd	Cash dividend of INR0.75 effective 01-09-2021
Mahindra Holidays & Resorts India Ltd	Corporate meeting effective 01-09-2021
Hatsun Agro Product Ltd	Corporate meeting effective 01-09-2021
Eris Lifesciences Ltd	Corporate meeting effective 01-09-2021

Domestic Events

- India Markit Manufacturing PMI for August 2021.

Global Events

- China Caixin Manufacturing PMI for August 2021.
- Japan Jibun Bank Manufacturing PMI for August 2021.
- The U.S. Manufacturing PMI for August 2021.
- The U.S. MBA Mortgage Applications for August 27, 2021.
- The U.S. ADP Employment Change for August 2021.
- Euro Area Manufacturing PMI for August 2021.
- Euro Area Unemployment Rate for July 2021.

Source of News : The content may have been taken from The Economic Times, Business Standard, Business Line, Mint and other leading financial newspapers and financial portals BSE,NSE, Bloomberg, Moneycontrol & others.

Analyst Certification:

We /I, Deepankar Saha & Jaydeb Dey Research Analyst(s) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the Financial Instruments of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report. Or at the time of Public Appearance. SMIFS does not have proprietary trades but may at a future date, may opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/ short position in the above Scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing. The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

Neither the Research Analysts nor SMIFS have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

For queries related to compliance of the report, please contact: -

Sudipto Datta, Compliance Officer

SMIFS Limited.

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5414 /91 33 6634 5414

Email Id.: compliance@smifs.com

Website: www.smifs.com